Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour. (Q38936576)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

title

Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Hojjat Ahmadzadehfar

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

6

Markus Essler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

author name string

Karin Mayer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Peter Brossart

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Maria A Gonzalez-Carmona

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Christian P Strassburg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

publication date

1 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Nuclear Medicine and Molecular Imaging

4 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

page(s)

1207-1214

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-017-3652-1

4 April 2020

exact match

0 references

cites work

Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Lutetium-labelled peptides for therapy of neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3652-1

Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE

21 January 2018

1 reference

12 December 2020

Yttrium-90-labelled somatostatin-analogue for cancer treatment

1 reference

12 December 2020

Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

12 December 2020

177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study

1 reference

12 December 2020

Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours

1 reference

12 December 2020

The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer

1 reference

12 December 2020

10.1007/S00259-017-3652-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28246882%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1 reference